Operations with this Structure (NSC 77427):

| | Format: MDL Molfile | Fields: | |
|-------------------------|--|--|----------|
| Structure Retrieval: | 3D ⊜ Strip H ⊜ File Name: NSC ⊝ Name ⊜ | NSC Number Molecular Weight Name (ACD) All Names | Retrieve |
| Cell Screens: | Yeast Screen Format: HTML | • | Retrieve |
| Visualization: | Format: TwirlyMol : | | Display |
| | Str | ructure Data: | |

| | NSC Number: | 77427 | Date: | 2011-09-21 05:38 |
|-------------------------|---|--|---|----------------------|
| | File Record: | 62076 | CAS Number: | 2846-77-7 |
| | Formula: | C ₆ H ₉ ClN ₄ O | Weight: | 188.6163 gr/mol |
| | Complexity: | 136.7 | Anti-HIV Screening: | No data available |
| | Druglikeness(std): Druglikeness(neg): WDI Record: | Is drug Is drug No | <pre>logP(KOW): logP(exp): logP(ACD):</pre> | No data No data |
| | H-Bond Acceptors: H-Bond Donors: | 5 3 | Available on DTP Plates: | Yes |
| | # Rotatable Bonds: (CACTVS) | 3 | WLN: | No data |
| | Stereochemistry Potential <i>R/S atoms and E/Z bonds</i> | No | Yeast Screen Level | 1 |
| Transfer to Java Editor | # Catalyst Conformers: (0 if Catalyst could not handle structure) | 21 | Matched Conformer: | None |
| Composition | C 20 2107 II 4 0107 NI 20 7007 CI 10 0007 O 0 407 | 77 | | |

Composition: C 38.21% H 4.81% N 29.70% Cl 18.80% O 8.48%

SMILES: NC1=NC(=CC(=N1)Cl)NCCO

Name: 2-((2-amino-6-chloro-4-pyrimidinyl)amino)ethanol (ACD/Name 4.0)

Commercial Availability: No **Commercial Database Keys:** None **Available Screening Data:** Yeast

Anti-HIV Screening: No data (EC_{50}/IC_{50}) available. **Cancer Screening Summary:** No data $(GI_{50}/TGI/LC_{50})$ available.

Predicted Activity **PASS Predictions:**

| | <u> </u> | ± \ | , |
|-----------------------------------|----------|-------|---|
| Acetylcholine agonist | 0.199 | 0.085 | |
| Acetylcholine muscarinic agonist | 0.123 | 0.093 | |
| Acetylcholine nicotinic agonist | 0.181 | 0.136 | |
| Adenosine A2a receptor agonist | 0.195 | 0.025 | |
| Adenosine A2a receptor antagonist | 0.072 | 0.032 | |
| Adenosine A2 receptor agonist | 0.038 | 0.016 | |
| Adenosine A2 receptor antagonist | 0.068 | 0.041 | |
| Adenosine A3 receptor antagonist | 0.286 | 0.210 | |
| Alcohol dehydrogenase inhibitor | 0.261 | 0.199 | |
| Antibiotic Trimethoprim-like | 0.127 | 0.006 | |
| Antihypercholesterolemic | 0.314 | 0.096 | |
| Antiinfective (HIV) | 0.505 | 0.030 | |
| Antimalarial | 0.247 | 0.061 | |
| Antimetabolite | 0.267 | 0.016 | |
| Antineoplastic | 0.317 | 0.135 | |
| Antiobesity | 0.223 | 0.134 | |
| | | | |

p(inactive)


p(active)


Enhanced NCI Database Browser 9/21/11 5:40 AM

| Antiprotozoal | 0.338 | 0.053 |
|--|-------|-------|
| Antismoking | 0.569 | 0.012 |
| Antitrichomonal | 0.270 | 0.071 |
| Antitrypanosomal | 0.333 | 0.036 |
| Antiviral | 0.685 | 0.009 |
| Antiviral (HIV) | 0.433 | 0.016 |
| Antiviral (influenza) | 0.123 | 0.001 |
| Atherosclerosis treatment | 0.581 | 0.085 |
| Benzodiazepine agonist partial | 0.213 | 0.042 |
| Cannabinoid receptor agonist | 0.254 | 0.037 |
| Carcinogenic | 0.219 | 0.081 |
| Cholinergic agonist | 0.290 | 0.200 |
| Cytostatic | 0.391 | 0.048 |
| Dihydrofolate reductase inhibitor | 0.147 | 0.006 |
| Diuretic | 0.237 | 0.129 |
| Erythropoietin | 0.490 | 0.020 |
| Glycinamide ribonucleotide formyltransferase inhibitor | 0.052 | 0.014 |
| Growth stimulant | 0.176 | 0.128 |
| HDL-cholesterol increasing | 0.323 | 0.110 |
| Hematopoietic inhibitor | 0.493 | 0.011 |
| 3 Hydroxyanthranilate oxygenase inhibitor | 0.296 | 0.148 |
| 5 Hydroxytryptamine 3 agonist | 0.614 | 0.008 |
| Hypoglycemic | 0.169 | 0.129 |
| Interferon inducer | 0.277 | 0.051 |
| Interleukin 6 antagonist | 0.377 | 0.221 |
| Interleukin 8 antagonist | 0.166 | 0.080 |
| Multiple sclerosis treatment | 0.584 | 0.064 |
| Neuropeptide antagonist | 0.313 | 0.100 |
| Neuropeptide Y antagonist | 0.313 | 0.100 |
| NMDA receptor glycine site agonist | 0.287 | 0.201 |
| Nucleotide metabolism regulator | 0.394 | 0.147 |
| O6-alkylquanine-DNA alkyltransferase inhibitor | 0.117 | 0.007 |
| Protein kinase C inhibitor | 0.274 | 0.042 |
| Purine nucleoside phosphorylase inhibitor | 0.068 | 0.019 |
| Purinergic P2 antagonist | 0.130 | 0.037 |
| Purinergic P2T antagonist | 0.091 | 0.030 |
| Purinergic receptor antagonist | 0.130 | 0.037 |
| Radiosensitizer | 0.243 | 0.155 |
| Reverse transcriptase inhibitor | 0.488 | 0.007 |
| Sclerosant | 0.232 | 0.203 |
| Septic shock treatment | 0.369 | 0.109 |
| Sodium channel blocker | 0.464 | 0.029 |
| Thymidylate synthase inhibitor | 0.111 | 0.029 |
| Topoisomerase II inhibitor | 0.525 | 0.014 |
| Tumour necrosis factor antagonist | 0.180 | 0.145 |
| Tyrosine kinase inhibitor | 0.159 | 0.143 |
| Urokinase inhibitor | 0.139 | 0.122 |
| Vitamin | 0.249 | 0.107 |
| VICANIII | 0.249 | 0.181 |

Enhanced NCI database browser 2.1

Operations with this Structure (NSC 619198):





| | | - / | | |
|-----------------------------|-------------------|--------------------------|----------------------|--|
| Formula: | $C_8H_{13}CIN_4O$ | Weight• | 216.6699 gr/mol | |
| Complexity: | 160.3 | | No data available | |
| Druglikeness(std): | Is drug | logP(KOW): | 0.16 | |
| Druglikeness(neg): | Is drug | logP(exp): | No data | |
| WDI Record: | No | logP(ACD): | No data | |
| H-Bond Acceptors: | 5 | Available on | X 7 | |
| H-Bond Donors: | 3 | Available on DTP Plates: | Yes | |
| # Rotatable Bonds: (CACTVS) | 5 | WLN: | No data | |
| Stereochemistry Potential | No | Yeast Screen | 1 | |

No

25

Screen

Level

Matched Conformer: None

1

Catalyst Conformers: Transfer to Java Editor (0 if Catalyst could not handle structure)

C 44.35% H 6.05% N 25.86% Cl 16.36% O 7.38%

R/S atoms and E/Z bonds

SMILES: NC1=NC(=CC(=N1)NCCCCO)Cl

4-((2-amino-6-chloro-4-pyrimidinyl)amino)-1-butanol (ACD/Name 4.0) Name:

Commercial Availability: No **Commercial Database Keys:** None

Available Screening Data: TGI, LC₅₀, GI₅₀, Yeast

No data (EC₅₀/IC₅₀) available. **Anti-HIV Screening:**

Cancer Screening Summary:

Composition:

| Cell | log(Cond | centration) | -log(GI ₅₀) | -log(TGI) | -log(LC ₅₀) |
|--------|----------|-------------|-------------------------|-----------|-------------------------|
| NCI-H | 23 | -4.00m | 4.000 | 4.000 | 4.000 |
| A549/. | ATCC | -4.00m | 4.000 | 4.000 | 4.000 |
| EKVX | | -4.00m | 4.000 | 4.000 | 4.000 |
| NCI-H | 226 | -4.00m | 4.000 | 4.000 | 4.000 |
| NCI-H | 322M | -4.00m | 4.000 | 4.000 | 4.000 |
| NCI-H | 460 | -4.00m | 4.000 | 4.000 | 4.000 |
| HOP-1 | 8 | -4.00m | 4.000 | 4.000 | 4.000 |
| HOP-9 | 2 | -4.00m | 4.000 | 4.000 | 4.000 |
| LXFL | 529 | -4.00m | 4.000 | 4.000 | 4.000 |
| DMS 1 | 14 | -4.00m | 4.000 | 4.000 | 4.000 |
| DMS 2 | 73 | -4.00m | 4.000 | 4.000 | 4.000 |
| HT29 | | -4.00m | 4.000 | 4.000 | 4.000 |
| HCC-2 | 998 | -4.00m | 4.000 | 4.000 | 4.000 |
| HCT-1 | 16 | -4.00m | 4.000 | 4.000 | 4.000 |
| SW-62 | 0 | -4.00m | 4.000 | 4.000 | 4.000 |
| COLO | 205 | -4.00m | 4.000 | 4.000 | 4.000 |
| DLD-1 | | -4.00m | 4.000 | 4.000 | 4.000 |

| HCT-15 | -4.00m | 4.000 | 4.000 | 4.000 |
|-----------|--------|-------|-------|-------|
| KM12 | -4.00m | 4.000 | 4.000 | 4.000 |
| KM20L2 | -4.00m | 4.000 | 4.000 | 4.000 |
| OVCAR-4 | -4.00m | 4.000 | 4.000 | 4.000 |
| OVCAR-5 | -4.00m | 4.000 | 4.000 | 4.000 |
| OVCAR-8 | -4.00m | 4.000 | 4.000 | 4.000 |
| IGR-OV1 | -4.00m | 4.000 | 4.000 | 4.000 |
| SK-OV-3 | -4.00m | 4.000 | 4.000 | 4.000 |
| CCRF-CEM | -4.00m | 4.000 | 4.000 | 4.000 |
| K-562 | -4.00m | 4.000 | 4.000 | 4.000 |
| MOLT-4 | -4.00m | 4.000 | 4.000 | 4.000 |
| HL-60(TB) | -4.00m | 4.000 | 4.000 | 4.000 |
| RPMI-8226 | -4.00m | 4.000 | 4.000 | 4.000 |
| SR | -4.00m | 4.000 | 4.000 | 4.000 |
| UO-31 | -4.00m | 4.000 | 4.000 | 4.000 |
| SN12C | -4.00m | 4.000 | 4.000 | 4.000 |
| A498 | -4.00m | 4.000 | 4.000 | 4.000 |
| RXF-393 | -4.00m | 4.000 | 4.000 | 4.000 |
| RXF-631 | -4.00m | 4.000 | 4.000 | 4.000 |
| ACHN | -4.00m | 4.000 | 4.000 | 4.000 |
| TK-10 | -4.00m | 4.000 | 4.000 | 4.000 |
| LOX IMVI | -4.00m | 4.000 | 4.000 | 4.000 |
| MALME-3M | -4.00m | 4.000 | 4.000 | 4.000 |
| SK-MEL-2 | -4.00m | 4.000 | 4.000 | 4.000 |
| SK-MEL-5 | -4.00m | 4.000 | 4.000 | 4.000 |
| SK-MEL-28 | -4.00m | 4.000 | 4.000 | 4.000 |
| M19-MEL | -4.00m | 4.000 | 4.000 | 4.000 |
| UACC-62 | -4.00m | 4.000 | 4.000 | 4.000 |
| UACC-257 | -4.00m | 4.000 | 4.000 | 4.000 |
| SNB-19 | -4.00m | 4.000 | 4.000 | 4.000 |
| SNB-75 | -4.00m | 4.185 | 4.000 | 4.000 |
| SNB-78 | -4.00m | 4.798 | 4.000 | 4.000 |
| U251 | -4.00m | 4.000 | 4.000 | 4.000 |
| SF-268 | -4.00m | 4.000 | 4.000 | 4.000 |
| SF-295 | -4.00m | 4.000 | 4.000 | 4.000 |
| SF-539 | -4.00m | 4.000 | 4.000 | 4.000 |
| XF 498 | -4.00m | 4.000 | 4.000 | 4.000 |


PASS Predictions:

| XF 498 | -4.00m | 4.000 | 4.000 | 4.000 | |
|------------------|---------------|--------------|-------|-----------|-------|
| Predicted Activi | - | | | p(active) | - ` / |
| Acetylcholine ag | onist | | | 0.224 | 0.061 |
| Acetylcholine mu | - | | | 0.117 | 0.109 |
| Acetylcholine ni | .cotinic agor | nist | | 0.282 | 0.050 |
| Adenosine A2a re | | | | 0.183 | 0.030 |
| Adenosine A2a re | | • | | 0.065 | 0.047 |
| Adenosine A2 rec | | | | 0.031 | 0.020 |
| Adenosine deamin | ase inhibito | or | | 0.044 | 0.036 |
| Antibiotic Trime | thoprim-like | j | | 0.112 | 0.006 |
| Antihypercholest | erolemic | | | 0.293 | 0.113 |
| Antiinfective (H | IV) | | | 0.549 | 0.021 |
| Antimalarial | | | | 0.306 | 0.029 |
| Antimetabolite | | | | 0.247 | 0.018 |
| Antineoplastic | | | | 0.283 | 0.157 |
| Antiobesity | | | | 0.274 | 0.079 |
| Antiosteoporotic | ! | | | 0.224 | 0.154 |
| Antiprotozoal | | | | 0.387 | 0.035 |
| Antismoking | | | | 0.495 | 0.019 |
| Antitrichomonal | | | | 0.311 | 0.045 |
| Antitrypanosomal | | | | 0.338 | 0.033 |
| Antiviral | | | | 0.673 | 0.010 |
| Antiviral (HIV) | | | | 0.426 | 0.017 |
| Antiviral (influ | enza) | | | 0.109 | 0.002 |
| Atherosclerosis | treatment | | | 0.636 | 0.058 |
| Benzodiazepine a | gonist parti | lal | | 0.181 | 0.064 |
| Bone formation s | timulant | | | 0.278 | 0.197 |
| Carcinogenic | | | | 0.158 | 0.130 |
| Cholinergic agon | ist | | | 0.310 | 0.174 |
| Cytostatic | | | | 0.375 | 0.055 |

| Dihydrofolate reductase inhibitor | 0.126 | 0.006 |
|--|-------|-------|
| Diuretic | 0.228 | 0.147 |
| Erythropoietin | 0.453 | 0.027 |
| Factor VIIa inhibitor | 0.284 | 0.219 |
| Geranylgeranyltransferase inhibitor | 0.326 | 0.289 |
| Glycinamide ribonucleotide formyltransferase inhibitor | 0.048 | 0.017 |
| Growth stimulant | 0.166 | 0.148 |
| Hair growth promoter | 0.191 | 0.058 |
| HDL-cholesterol increasing | 0.299 | 0.131 |
| Hematopoietic inhibitor | 0.459 | 0.014 |
| 3 Hydroxyanthranilate oxygenase inhibitor | 0.295 | 0.155 |
| 5 Hydroxytryptamine 3 agonist | 0.546 | 0.014 |
| Hypnotic | 0.360 | 0.308 |
| Interferon inducer | 0.275 | 0.054 |
| Interleukin 6 antagonist | 0.362 | 0.272 |
| Interleukin 8 antagonist | 0.162 | 0.091 |
| Maillard reaction inhibitor | 0.161 | 0.136 |
| Multiple sclerosis treatment | 0.642 | 0.043 |
| Muscle relaxant | 0.218 | 0.177 |
| Myocardial ischemia treatment | 0.352 | 0.219 |
| Neuropeptide antagonist | 0.360 | 0.067 |
| Neuropeptide Y antagonist | 0.360 | 0.067 |
| Nucleotide metabolism regulator | 0.311 | 0.220 |
| O6-alkylquanine-DNA alkyltransferase inhibitor | 0.101 | 0.010 |
| Phospholipase C inhibitor | 0.485 | 0.087 |
| Protein kinase C inhibitor | 0.237 | 0.066 |
| Purine nucleoside phosphorylase inhibitor | 0.061 | 0.024 |
| Purinergic P2 antagonist | 0.159 | 0.023 |
| Purinergic P2T antagonist | 0.109 | 0.019 |
| Purinergic receptor antagonist | 0.159 | 0.023 |
| Radiosensitizer | 0.249 | 0.146 |
| Respiratory distress syndrome treatment | 0.333 | 0.290 |
| Reverse transcriptase inhibitor | 0.425 | 0.009 |
| Saluretic | 0.159 | 0.151 |
| Septic shock treatment | 0.448 | 0.059 |
| Skeletal muscle relaxant | 0.220 | 0.175 |
| Sodium channel blocker | 0.428 | 0.046 |
| Teratogen | 0.229 | 0.166 |
| Teratogen and/or embryotoxic | 0.229 | 0.166 |
| Thymidine kinase inhibitor | 0.319 | 0.068 |
| Thymidylate synthase inhibitor | 0.095 | 0.020 |
| Topoisomerase II inhibitor | 0.382 | 0.236 |
| Tumour necrosis factor antagonist | 0.214 | 0.078 |
| Urokinase inhibitor | 0.323 | 0.128 |
| | 0.020 | |

Enhanced NCI database browser 2.1

Operations with this Structure (NSC 636346):



Structure Data:

| | NSC Number: | 636346 | Date: | 2011-09-07 04:58 |
|-------------------------|---|--------------------------|---|---------------------|
| | File Record: | 219796 | CAS Number: | (None) |
| | Formula: | $C_{13}H_{12}ClNO_3$ | Weight: | 265.6957 gr/mol |
| | Complexity: | 345.1 | Anti-HIV Screening: | Confimed inactive |
| | Druglikeness(std): Druglikeness(neg): WDI Record: | No drug No drug No | <pre>logP(KOW): logP(exp): logP(ACD):</pre> | No data |
| | H-Bond Acceptors: H-Bond Donors: | 4 0 | Available on DTP Plates: | Yes |
| · | # Rotatable Bonds: (CACTVS) | 4 | WLN: | No data |
| | Stereochemistry Potential R/S atoms and E/Z bonds | Yes | Yeast Screen Level | 0 |
| Transfer to Java Editor | # Catalyst Conformers: (0 if Catalyst could not handle structure) | 8 | Matched Conformer: | None |
| Composition: | C 58.77% H 4.55% N 5.27% Cl 13.34% C | 18.07% | | |

Composition: C 58.77% H 4.55% N 5.27% Cl 13.34% O 18.07% SMILES: CCOC=C1N=C(OC1=O)C(Cl)C2=CC=CC=C2

Name: 2-(chloro(phenyl)methyl)-4-(ethoxymethylene)-1,3-oxazol-5(4H)-one (ACD/Name

4.0)

Commercial Availability: No **Commercial Database Keys:** None

Available Screening Data: TGI, LC₅₀, GI₅₀, EC₅₀, IC₅₀
Anti-HIV Screening: Conclusion: Confirmed Inactive

 $IC_{50}(0.0001 \text{ m}) > 0.0001$ $EC_{50}(0.0001 \text{ m}) > 0.0001$

Cancer Screening Summary: Cell log(Concentration) -log(GI₅₀) -log(TGI) -log(LC₅₀)

| NCI-H23 | -4.00m | 4.000 | 4.000 | 4.000 |
|-----------|--------|-------|-------|-------|
| NCI-H522 | -4.00m | 4.000 | 4.000 | 4.000 |
| A549/ATCC | -4.00m | 4.000 | 4.000 | 4.000 |
| EKVX | -4.00m | 4.000 | 4.000 | 4.000 |
| NCI-H226 | -4.00m | 4.000 | 4.000 | 4.000 |
| NCI-H322M | -4.00m | 4.000 | 4.000 | 4.000 |
| NCI-H460 | -4.00m | 4.000 | 4.000 | 4.000 |
| HOP-62 | -4.00m | 4.000 | 4.000 | 4.000 |

| HOP-92 | -4.00m | 4.000 | 4.000 | 4.000 |
|-----------|-------------|------------|-----------|------------|
| | -4.00m | | | |
| LXFL 529 | | 4.000 | 4.000 | 4.000 |
| DMS 114 | -4.00m | 4.211 | 4.000 | 4.000 |
| DMS 273 | -4.00m | 4.000 | 4.000 | 4.000 |
| HT29 | -4.00m | 4.000 | 4.000 | 4.000 |
| HCC-2998 | -4.00m | 4.000 | 4.000 | 4.000 |
| SW-620 | -4.00m | 4.000 | 4.000 | 4.000 |
| COLO 205 | -4.00m | 4.000 | 4.000 | 4.000 |
| DLD-1 | -4.00m | 4.000 | 4.000 | 4.000 |
| HCT-15 | -4.00m | 4.000 | 4.000 | 4.000 |
| KM12 | -4.00m | 4.000 | 4.000 | 4.000 |
| KM20L2 | -4.00m | 4.000 | 4.000 | 4.000 |
| OVCAR-3 | -4.00m | 4.000 | 4.000 | 4.000 |
| OVCAR-4 | -4.00m | 4.000 | 4.000 | 4.000 |
| OVCAR-5 | -4.00m | 4.000 | 4.000 | 4.000 |
| OVCAR-8 | -4.00m | 4.000 | 4.000 | 4.000 |
| IGR-OV1 | -4.00m | 4.000 | 4.000 | 4.000 |
| CCRF-CEM | -4.00m | 4.000 | 4.000 | 4.000 |
| K-562 | -4.00m | 4.000 | 4.000 | 4.000 |
| MOLT-4 | -4.00m | 4.000 | 4.000 | 4.000 |
| HL-60(TB) | -4.00m | 4.000 | 4.000 | 4.000 |
| RPMI-8226 | -4.00m | 4.000 | 4.000 | 4.000 |
| UO-31 | -4.00m | 4.000 | 4.000 | 4.000 |
| SN12C | -4.00m | 4.000 | 4.000 | 4.000 |
| A498 | -4.00m | 4.000 | 4.000 | 4.000 |
| CAKI-1 | -4.00m | 4.000 | 4.000 | 4.000 |
| RXF-393 | -4.00m | 4.000 | 4.000 | 4.000 |
| 786-0 | -4.00m | 4.000 | 4.000 | 4.000 |
| ACHN | -4.00m | 4.000 | 4.000 | 4.000 |
| TK-10 | -4.00m | 4.000 | 4.000 | 4.000 |
| LOX IMVI | -4.00m | 4.000 | 4.000 | 4.000 |
| MALME-3M | -4.00m | 4.000 | 4.000 | 4.000 |
| SK-MEL-2 | -4.00m | 4.000 | 4.000 | 4.000 |
| SK-MEL-5 | -4.00m | 4.000 | 4.000 | 4.000 |
| SK-MEL-28 | -4.00m | 4.000 | 4.000 | 4.000 |
| M14 | -4.00m | 4.000 | 4.000 | 4.000 |
| M19-MEL | -4.00m | 4.000 | 4.000 | 4.000 |
| UACC-62 | -4.00m | 4.000 | 4.000 | 4.000 |
| UACC-257 | -4.00m | 4.000 | 4.000 | 4.000 |
| SNB-19 | -4.00m | 4.000 | 4.000 | 4.000 |
| SNB-75 | -4.00m | 4.000 | 4.000 | 4.000 |
| SNB-78 | -4.00m | 4.000 | 4.000 | 4.000 |
| SF-268 | -4.00m | 4.000 | 4.000 | 4.000 |
| SF-295 | -4.00m | 4.000 | 4.000 | 4.000 |
| SF-539 | -4.00m | 4.000 | 4.000 | 4.000 |
| XF 498 | -4.00m | 4.000 | 4.000 | 4.000 |
| SK-OV-3 | -4.00m | (No data) | (No data) | (No data) |
| 21. 0. 0 | 4 • 0 0 III | (iii daca) | (aaca) | (1.0 aaca) |

PASS Predictions:

| SK-0V-3 | -4.00m | (No data) | (No data) | (NO data |) |
|-------------------|------------|-------------|-----------|-----------|-------------|
| Predicted Activi | ty | | | p(active) | p(inactive) |
| Acetylcholine ag | onist | | | 0.193 | 0.091 |
| Acetylcholine and | tagonist | | | 0.154 | 0.148 |
| Acetylcholine M1 | receptor | agonist | | 0.096 | 0.070 |
| Acetylcholine M2 | receptor | antagonist | | 0.173 | 0.143 |
| Acetylcholine M3 | receptor | antagonist | | 0.202 | 0.100 |
| Acetylcholine mu | scarinic a | agonist | | 0.131 | 0.075 |
| Acetylcholine mu | scarinic a | antagonist | | 0.173 | 0.125 |
| Acetylcholine ni | cotinic a | gonist | | 0.281 | 0.051 |
| Acetylcholine ni | cotinic a | ntagonist | | 0.181 | 0.092 |
| Acetylcholine re | lease stir | mulant | | 0.373 | 0.045 |
| Acute neurologic | disorders | s treatment | | 0.231 | 0.221 |
| Adenosine A2a re | ceptor and | tagonist | | 0.062 | 0.057 |
| Adenosine A3 rec | eptor anta | agonist | | 0.337 | 0.086 |
| Adenosine kinase | inhibito | r | | 0.111 | 0.110 |
| | | | | | |

| ADP ribosyl transferase inhibitor | 0.306 | 0.026 |
|---|-------|-------|
| Adrenergic transmitter uptake inhibitor | 0.415 | 0.104 |
| Alcohol dehydrogenase inhibitor | 0.300 | 0.048 |
| Aldosterone antagonist | 0.198 | 0.067 |
| Alkylator | 0.106 | 0.078 |
| Alkylphospholipid | 0.074 | 0.053 |
| | | |
| Alpha 1 adrenoreceptor agonist | 0.285 | 0.055 |
| Alpha 2 adrenoreceptor agonist | 0.149 | 0.059 |
| Alpha adrenoreceptor agonist | 0.130 | 0.072 |
| Alpha glucosidase inhibitor | 0.065 | 0.065 |
| Alzheimer's disease treatment | 0.434 | 0.057 |
| Aminopeptidase microsomal inhibitor | 0.329 | 0.086 |
| AMPA receptor agonist | 0.120 | 0.043 |
| Anabolic | 0.160 | 0.063 |
| Analeptic | 0.383 | 0.047 |
| Androgen agonist | 0.077 | 0.058 |
| Anesthetic | 0.200 | 0.122 |
| | 0.251 | |
| Anesthetic general | | 0.067 |
| Anesthetic inhalation | 0.374 | 0.012 |
| Anesthetic local | 0.196 | 0.120 |
| Angiogenesis inhibitor | 0.275 | 0.215 |
| Anorexic | 0.336 | 0.048 |
| Antiamebic | 0.303 | 0.069 |
| Antiasthmatic | 0.313 | 0.183 |
| Anticataract | 0.290 | 0.079 |
| Anticerebroischemic | 0.320 | 0.169 |
| Anticoccidial | 0.190 | 0.107 |
| Anticonvulsant | 0.248 | 0.186 |
| Antidepressant, Imipramin-like | 0.187 | 0.090 |
| Antidiabetic | 0.211 | 0.134 |
| Antidiabetic symptomatic | 0.171 | 0.124 |
| | 0.457 | 0.093 |
| Antidyskinetic | | |
| Antiemphysemic | 0.122 | 0.111 |
| Antifungal | 0.228 | 0.167 |
| Antiglaucomic | 0.188 | 0.148 |
| Anti-Helicobacter pylori | 0.220 | 0.131 |
| Antihelmintic | 0.300 | 0.066 |
| Antihypercholesterolemic | 0.395 | 0.057 |
| Antiinfective (HIV) | 0.326 | 0.164 |
| Antiinflammatory, intestinal | 0.391 | 0.146 |
| Antiinflammatory, pancreatic | 0.341 | 0.152 |
| Antiischemic | 0.409 | 0.213 |
| Antilipidemic | 0.357 | 0.070 |
| Antimalarial | 0.190 | 0.128 |
| Antimycobacterial | 0.248 | 0.108 |
| Antineoplastic | 0.348 | 0.118 |
| Antineoplastic enhancer | 0.329 | 0.073 |
| Antioxidant | 0.191 | 0.119 |
| Antiparkinsonian, rigidity relieving | 0.355 | |
| | | 0.064 |
| Antiparkinsonian, tremor relieving | 0.294 | 0.078 |
| Antipruritic | 0.514 | 0.069 |
| Antipsoriatic | 0.256 | 0.189 |
| Antiseptic | 0.586 | 0.018 |
| Antismoking | 0.353 | 0.078 |
| Antispirochetal | 0.191 | 0.086 |
| Antitoxic | 0.376 | 0.063 |
| Antitrichomonal | 0.283 | 0.061 |
| Antitrypanosomal | 0.276 | 0.081 |
| Antitussive | 0.229 | 0.108 |
| Antitussive, narcotic | 0.197 | 0.086 |
| Antiulcerative | 0.261 | 0.182 |
| Antiviral | 0.306 | 0.109 |
| | | |

| Antiviral (hepatitis) | 0.428 | 0.031 |
|--|-------------------------|-------------------------|
| Antiviral (hepatitis C) | 0.337 | 0.034 |
| Arrhythmogenic | 0.562 | 0.106 |
| Atherosclerosis treatment | 0.443 | 0.193 |
| Benzodiazepine agonist partial | 0.153 | 0.109 |
| Benzodiazepine antagonist | 0.199 | 0.069 |
| Benzodiazepine inverse agonist | 0.089 | 0.056 |
| | | |
| Beta 1 adrenoreceptor agonist | 0.101 | 0.094 |
| Beta lactamase inhibitor | 0.072 | 0.062 |
| Bone formation stimulant | 0.400 | 0.088 |
| Bone resorption inhibitor | 0.329 | 0.114 |
| Calcium regulator | 0.286 | 0.102 |
| Calmodulin antagonist | 0.217 | 0.130 |
| Calpain inhibitor | 0.189 | 0.069 |
| cAMP phosphodiesterase inhibitor | 0.339 | 0.138 |
| Cannabinoid receptor agonist | 0.236 | 0.077 |
| Carcinogenic | 0.369 | 0.037 |
| Cardiodepressant | 0.303 | 0.151 |
| Cardioprotectant | 0.348 | 0.085 |
| Cardiotoxic | 0.337 | 0.072 |
| | 0.691 | 0.029 |
| Cardiovascular analeptic | | |
| Catechol O methyltransferase inhibitor | 0.265 | 0.067 |
| Cathepsin B inhibitor | 0.136 | 0.128 |
| Cathepsin L inhibitor | 0.298 | 0.048 |
| Chemopreventive | 0.556 | 0.048 |
| Choleretic | 0.261 | 0.076 |
| Cholesterol esterase inhibitor | 0.141 | 0.042 |
| Cholinergic agonist | 0.398 | 0.071 |
| Cholinergic antagonist | 0.135 | 0.084 |
| CNS active muscle relaxant | 0.383 | 0.065 |
| Coagulant | 0.171 | 0.037 |
| Cocain dependency treatment | 0.340 | 0.063 |
| Complement inhibitor | 0.394 | 0.206 |
| Contraceptive | 0.235 | 0.100 |
| Corneal wound healing stimulator | 0.285 | 0.222 |
| Cyclooxygenase inhibitor | 0.207 | 0.125 |
| Cystic fibrosis treatment | 0.330 | 0.106 |
| Cytokine modulator | 0.427 | 0.163 |
| | 0.427 | |
| Cytosole dipeptidase inhibitor | | 0.090 |
| Cytostatic | 0.330 | 0.079 |
| Dihydroorotate dehydrogenase inhibitor | 0.214 | 0.044 |
| Dipeptidyl aminopeptidase IV inhibitor | 0.171 | 0.067 |
| Diuretic | 0.233 | 0.136 |
| Dopa decarboxylase inhibitor | 0.309 | 0.048 |
| Dopamine beta hydroxylase inhibitor | 0.086 | 0.043 |
| Dopamine uptake inhibitor | 0.143 | 0.107 |
| Embryotoxic | 0.429 | 0.047 |
| Endothelin antagonist | 0.261 | 0.098 |
| Erythropoietin | 0.396 | 0.064 |
| Estrone sulfatase inhibitor | 0.144 | 0.101 |
| Excitatory amino acid agonist | 0.278 | 0.034 |
| Excitatory amino acid antagonist | 0.288 | 0.089 |
| Expectorant | 0.277 | 0.061 |
| Factor XIIIa inhibitor | 0.103 | 0.097 |
| GABA aminotransferase inhibitor | 0.149 | 0.056 |
| GABA A receptor agonist | 0.246 | 0.109 |
| - · · · · · · · · · · · · · · · · · · · | | 0.109 |
| GABA A receptor antagonist | Λ 161 | |
| CARA B regenter agenist | 0.161 | |
| GABA B receptor agonist | 0.218 | 0.041 |
| GABA B receptor antagonist | 0.218 0.127 | 0.041 0.042 |
| GABA B receptor antagonist GABA receptor agonist | 0.218 0.127 0.361 | 0.041 0.042 0.072 |
| GABA B receptor antagonist | 0.218 0.127 | 0.041 0.042 |

| Geranylgeranyltransferase inhibitor | 0.349 | 0.168 |
|---|-------|-------|
| Glucagon receptor antagonist | 0.255 | 0.126 |
| Glucose-6-phosphate translocase inhibitor | 0.179 | 0.085 |
| Glutamate (mGluRla) agonist | 0.119 | 0.030 |
| Glutamate (mGluR1) agonist | 0.094 | 0.034 |
| Glutamate (mGluR1) antagonist | 0.071 | 0.034 |
| , , , | | |
| Glutamate (mGluR2) agonist | 0.149 | 0.029 |
| Glutamate (mGluR2) antagonist | 0.115 | 0.043 |
| Glutamate (mGluR3) agonist | 0.120 | 0.034 |
| Glutamate (mGluR3) antagonist | 0.154 | 0.047 |
| Glutamate (mGluR5a) agonist | 0.119 | 0.030 |
| Glutamate (mGluR5) agonist | 0.192 | 0.031 |
| Glutamate (mGluR5) antagonist | 0.421 | 0.027 |
| Glutamate (mGluR6) agonist | 0.072 | 0.045 |
| , , , , , , , , , , , , , , , , , , , | | |
| Glutamate (mGluR6) antagonist | 0.159 | 0.039 |
| Glutamate (mGluR) agonist | 0.048 | 0.038 |
| Glutamate (mGluR) antagonist | 0.163 | 0.041 |
| Glutamate receptor agonist | 0.083 | 0.049 |
| Glutamate uptake inhibitor | 0.137 | 0.042 |
| Glycine receptor agonist | 0.288 | 0.028 |
| Gynecological disorders treatment | 0.214 | 0.180 |
| Hair growth promoter | 0.156 | 0.113 |
| HCV NS3-helicase inhibitor | 0.162 | 0.039 |
| HCV NS3 protease inhibitor | | |
| | 0.340 | 0.167 |
| HCV serine protease inhibitor | 0.231 | 0.163 |
| HDL-cholesterol increasing | 0.436 | 0.056 |
| Hematopoietic | 0.180 | 0.134 |
| Hematopoietic inhibitor | 0.381 | 0.033 |
| Hepatoprotectant | 0.320 | 0.070 |
| Hestagen antagonist | 0.345 | 0.071 |
| Histamine agonist | 0.072 | 0.044 |
| Histamine H1 receptor antagonist | 0.239 | 0.096 |
| Histamine H2 receptor agonist | 0.210 | 0.051 |
| | | |
| Histamine H3 receptor agonist | 0.071 | 0.033 |
| Histamine release stimulant | 0.442 | 0.085 |
| Histidine decarboxylase inhibitor | 0.110 | 0.056 |
| HIV integrase inhibitor | 0.384 | 0.087 |
| HMG CoA synthase inhibitor | 0.101 | 0.080 |
| 3 Hydroxyanthranilate oxygenase inhibitor | 0.319 | 0.051 |
| 5 Hydroxytryptamine 2 agonist | 0.342 | 0.088 |
| 5 Hydroxytryptamine 2B antagonist | 0.158 | 0.155 |
| 5 Hydroxytryptamine 2C agonist | 0.392 | 0.079 |
| 5 Hydroxytryptamine 3 agonist | 0.307 | 0.061 |
| 5 Hydroxytryptamine release stimulant | 0.389 | 0.070 |
| Hypertensive | 0.339 | 0.075 |
| | | |
| Hypertensive, ophthalmic | 0.271 | 0.051 |
| Hypertermic | 0.270 | 0.068 |
| Hypnotic | 0.529 | 0.041 |
| Hypoglycemic | 0.181 | 0.096 |
| Hypotermic | 0.443 | 0.110 |
| Ileal bile acid transport inhibitor | 0.150 | 0.141 |
| Immunostimulant | 0.234 | 0.225 |
| Immunosuppressant | 0.247 | 0.237 |
| Insulin promoter | 0.355 | 0.122 |
| Insulin secretagoues | 0.158 | 0.070 |
| | | |
| Interferon inducer | 0.246 | 0.098 |
| Interleukin 1 antagonist | 0.331 | 0.170 |
| Interleukin 6 antagonist | 0.415 | 0.105 |
| Interleukin 8 antagonist | 0.151 | 0.143 |
| Interleukin antagonist | 0.284 | 0.195 |
| Kainate receptor agonist | 0.111 | 0.056 |
| Kainate receptor antagonist | 0.123 | 0.087 |
| | | |

| Keratolytic | 0.493 | 0.076 |
|--|-------|-------|
| Keratoses actinic(solar) treatment | 0.352 | 0.068 |
| Leukopoiesis inhibitor | 0.428 | 0.045 |
| Lipid peroxidase inhibitor | 0.219 | 0.163 |
| Liver fibrosis treatment | 0.232 | 0.085 |
| Lymphocytopoiesis inhibitor | 0.175 | 0.070 |
| Maillard reaction inhibitor | 0.208 | 0.055 |
| | | |
| Male reproductive disfunction treatment | 0.398 | 0.177 |
| Mannosidase inhibitor | 0.214 | 0.031 |
| MAO-A inhibitor | 0.170 | 0.066 |
| MAO-B inhibitor | 0.098 | 0.068 |
| MAO inhibitor | 0.247 | 0.082 |
| Mediator release inhibitor | 0.285 | 0.156 |
| Melatonin antagonist | 0.344 | 0.067 |
| Metabolic | 0.565 | 0.105 |
| Miotic | 0.314 | 0.047 |
| Mucolytic | 0.198 | 0.062 |
| Multiple sclerosis treatment | 0.393 | 0.248 |
| Muscle relaxant | | |
| | 0.290 | 0.106 |
| Mutagenic | 0.237 | 0.041 |
| Mydriatic | 0.126 | 0.074 |
| Myocardial ischemia treatment | 0.386 | 0.175 |
| Narcotic antagonist | 0.228 | 0.131 |
| Nasal decongestant | 0.253 | 0.061 |
| Neurotrophic factor | 0.368 | 0.210 |
| Nitric oxide donor | 0.052 | 0.045 |
| Nitric oxide synthase inhibitor | 0.197 | 0.053 |
| NMDA receptor agonist | 0.185 | 0.038 |
| NMDA receptor antagonist | 0.106 | 0.095 |
| NMDA receptor glycine site agonist | 0.461 | 0.021 |
| NMDA receptor glycine site antagonist | 0.112 | 0.040 |
| NMDA receptor polyamine site activator | 0.209 | 0.022 |
| | | |
| NMDA receptor polyamine site blocker | 0.068 | 0.061 |
| Non-steroidal antiinflammatory agent | 0.303 | 0.065 |
| Nootropic | 0.469 | 0.058 |
| Nucleotide metabolism regulator | 0.464 | 0.100 |
| O6-alkylguanine-DNA alkyltransferase inhibitor | | 0.040 |
| Ophthalmic drug | 0.243 | 0.156 |
| Opioid antagonist | 0.135 | 0.118 |
| Opioid partial agonist | 0.179 | 0.167 |
| Ornithine decarboxylase inhibitor | 0.137 | 0.039 |
| 2,3-0xidosqualene-lanosterol cyclase inhibitor | 0.237 | 0.103 |
| Oxytocin agonist | 0.226 | 0.173 |
| Parathyroid hormone antagonist | 0.255 | 0.136 |
| Phosphodiesterase I inhibitor | 0.176 | 0.109 |
| Phosphodiesterase V Inhibitor | 0.195 | 0.189 |
| Phospholipase C inhibitor | 0.453 | 0.124 |
| Photosensitizer | 0.114 | 0.124 |
| | | |
| Platelet adhesion inhibitor | 0.397 | 0.054 |
| Platelet antagonist | 0.282 | 0.071 |
| Poly(ADP-ribose)synthethase inhibitor | 0.340 | 0.060 |
| Postcoital contraceptive | 0.138 | 0.120 |
| Progestin agonist | 0.130 | 0.076 |
| Prolactin inhibitor | 0.252 | 0.094 |
| Prolyl endopeptidase inhibitor | 0.058 | 0.056 |
| Prostaglandin antagonist | 0.274 | 0.102 |
| Protease inhibitor | 0.150 | 0.148 |
| Protocollagen prolyl hydroxylase inhibitor | 0.088 | 0.056 |
| Psychosexual dysfunction treatment | 0.397 | 0.151 |
| Psychostimulant | 0.445 | 0.053 |
| Quisqualate antagonist | 0.124 | 0.043 |
| Radioprotector | 0.383 | 0.050 |
| | | 0.050 |

| Radiosensitizer | 0.295 | 0.087 |
|---|-------|-------|
| Respiratory analeptic | 0.407 | 0.048 |
| Respiratory distress syndrome treatment | 0.367 | 0.242 |
| Reverse transcriptase inhibitor | 0.158 | 0.112 |
| Rhinitis treatment | 0.312 | 0.295 |
| Ribonucleotide reductase inhibitor | 0.140 | 0.132 |
| S-adenosyl-L-methionine decarboxylase inhibitor | 0.318 | 0.034 |
| Saluretic | 0.190 | 0.066 |
| Saluretic, reabsorbtion inhibitor | 0.129 | 0.068 |
| Sclerosant | 0.292 | 0.039 |
| Sedative | 0.322 | 0.140 |
| Skeletal muscle relaxant | 0.291 | 0.097 |
| Sodium channel blocker | 0.389 | 0.078 |
| Sodium channel blocker class Ib | 0.318 | 0.036 |
| Spasmogenic | 0.308 | 0.116 |
| Spasmolytic | 0.213 | 0.213 |
| Spasmolytic, Papaverin-like | 0.264 | 0.112 |
| Spasmolytic, urinary | 0.264 | 0.177 |
| Spermicide | 0.592 | 0.053 |
| Squalene epoxidase inhibitor | 0.161 | 0.080 |
| Succinic dehydrogenase inhibitor | 0.150 | 0.044 |
| Sympatholytic | 0.350 | 0.083 |
| Teratogen | 0.410 | 0.048 |
| Teratogen and/or embryotoxic | 0.410 | 0.048 |
| Thrombolytic | 0.274 | 0.102 |
| Thymidine kinase inhibitor | 0.312 | 0.086 |
| Thyroid hormone agonist | 0.113 | 0.070 |
| Thyroid hormone antagonist | 0.169 | 0.034 |
| TNF-alpha release inhibitor | 0.488 | 0.091 |
| Topoisomerase II inhibitor | 0.450 | 0.105 |
| Tyrosine kinase inhibitor | 0.148 | 0.141 |
| Ulcerogenic | 0.282 | 0.064 |
| Uricosuric | 0.432 | 0.078 |
| Uridine phosphorylase inhibitor | 0.112 | 0.058 |
| Urokinase inhibitor | 0.320 | 0.135 |
| Vasodilator | 0.223 | 0.222 |
| Vasopressor | 0.294 | 0.232 |
| Vitamin | 0.268 | 0.120 |
| Xanthine oxidase inhibitor | 0.251 | 0.084 |

Enhanced NCI database browser 2.1